share_log

Novavax | 4: Statement of changes in beneficial ownership of securities-Director MOTT DAVID M

Novavax | 4: Statement of changes in beneficial ownership of securities-Director MOTT DAVID M

諾瓦瓦克斯醫藥 | 4：持股變動聲明-董事 MOTT DAVID M
美股sec公告 ·  06/15 04:29
牛牛AI助理已提取核心訊息
David M. Mott, reported a completed transaction involving the acquisition of 6,670 shares of Novavax Inc (NVAX) common stock on June 12, 2024. The shares were acquired at a price of $0.00, indicating the transaction was likely an exercise or conversion of derivative securities. Following this transaction, Mott's direct holdings in Novavax increased to a total of 50,470 shares. The nature of the transaction suggests an investment in the company's growth and potential, as Mott increases his stake in the pharmaceutical firm.
David M. Mott, reported a completed transaction involving the acquisition of 6,670 shares of Novavax Inc (NVAX) common stock on June 12, 2024. The shares were acquired at a price of $0.00, indicating the transaction was likely an exercise or conversion of derivative securities. Following this transaction, Mott's direct holdings in Novavax increased to a total of 50,470 shares. The nature of the transaction suggests an investment in the company's growth and potential, as Mott increases his stake in the pharmaceutical firm.
2024年6月12日，David M. Mott報告完成了一筆交易，收購了6,670股諾瓦瓦克斯醫藥（NVAX）普通股。這些股票的價格爲0.00美元，表明該交易可能是衍生證券的行權或轉換。此次交易後，莫特在諾瓦瓦克斯醫藥的直接持股增至50,470股。交易的性質表明莫特在該藥品公司的創業板和潛力方面增加了持股。
2024年6月12日，David M. Mott報告完成了一筆交易，收購了6,670股諾瓦瓦克斯醫藥（NVAX）普通股。這些股票的價格爲0.00美元，表明該交易可能是衍生證券的行權或轉換。此次交易後，莫特在諾瓦瓦克斯醫藥的直接持股增至50,470股。交易的性質表明莫特在該藥品公司的創業板和潛力方面增加了持股。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。